Hill-Rom Holdings Shares Outstanding 2006-2018 | HRC

Hill-Rom Holdings shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Hill-Rom Holdings shares outstanding for the quarter ending September 30, 2018 were 0.068B, a 0.88% increase year-over-year.
  • Hill-Rom Holdings 2018 shares outstanding were 0.068B, a 0.58% increase from 2017.
  • Hill-Rom Holdings 2017 shares outstanding were 0.067B, a 0.94% increase from 2016.
  • Hill-Rom Holdings 2016 shares outstanding were 0.067B, a 13.77% increase from 2015.
Hill-Rom Holdings Annual Shares Outstanding
(Millions of Shares)
2018 68
2017 67
2016 67
2015 59
2014 59
2013 60
2012 62
2011 64
2010 64
2009 63
2008 63
2007 62
2006 62
2005 62
Hill-Rom Holdings Quarterly Shares Outstanding
(Millions of Shares)
Q4 2018 68
Q3 2018 68
Q2 2018 68
Q1 2017 67
Q4 2017 67
Q3 2017 68
Q2 2017 67
Q1 2016 67
Q4 2016 67
Q3 2016 67
Q2 2016 66
Q1 2015 66
Q4 2015 59
Q3 2015 58
Q2 2015 58
Q1 2014 58
Q4 2014 59
Q3 2014 58
Q2 2014 57
Q1 2013 59
Q4 2013 60
Q3 2013 60
Q2 2013 61
Q1 2012 61
Q4 2012 62
Q3 2012 63
Q2 2012 63
Q1 2011 62
Q4 2011 64
Q3 2011 64
Q2 2011 64
Q1 2010 64
Q4 2010 64
Q3 2010 64
Q2 2010 64
Q1 2009 63
Q4 2009 63
Q3 2009 63
Q2 2009 63
Q1 2008 63
Q4 2008 63
Q3 2008 63
Q2 2008 63
Q1 2007 62
Q4 2007 62
Q3 2007 62
Q2 2007 62
Q1 2006 62
Q4 2006 62
Q3 2006 62
Q2 2006 62
Q1 2005 61
Q4 2005 62
Q3 2005 62
Q2 2005 62
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $6.270B $2.470B
HILL-ROM HOLDINGS, Inc. traces its roots back to 1929 when William A. Hillenbrand formed the company as a division of Hillenbrand Industries. At that time, the company was focused on developing innovative beds and furnishings for hospital patient rooms. Now, after nearly eighty years, Hill-Rom leads the way as an innovator in the medical technology field developing solutions that enhance outcomes for patients and their caregivers.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.543B 19.40
Abbott Laboratories (ABT) United States $126.526B 25.64
Stryker (SYK) United States $64.420B 24.28
Boston Scientific (BSX) United States $51.491B 26.02
Baxter (BAX) United States $35.393B 22.86
Zimmer Biomet Holdings (ZBH) United States $23.875B 15.48
Smith & Nephew SNATS (SNN) United Kingdom $16.038B 0.00
ResMed (RMD) United States $14.846B 28.31
Perrigo (PRGO) Ireland $8.596B 13.05
Bio-Rad Laboratories (BIO) United States $8.274B 52.91
Canopy Growth (CGC) Canada $8.174B 0.00
Aurora Cannabis (ACB) Canada $6.172B 33.68
Haemonetics (HAE) United States $5.727B 50.36
ICU Medical (ICUI) United States $4.968B 27.68
Insulet (PODD) United States $4.838B 0.00
Agios Pharmaceuticals (AGIO) United States $4.052B 0.00
Hutchison China MediTech (HCM) China $4.010B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.990B 0.00
Neogen (NEOG) United States $3.294B 49.88
NuVasive (NUVA) United States $3.166B 29.46
National Vision Holdings (EYE) United States $3.024B 58.49
Quidel (QDEL) United States $2.507B 32.68
Aphria (APHA) $2.433B 0.00
NxStage Medical (NXTM) United States $1.933B 0.00
Phibro Animal Health (PAHC) United States $1.409B 19.95
AtriCure (ATRC) United States $1.241B 0.00
Cardiovascular Systems (CSII) United States $1.058B 1524.50
VAREX IMAGING (VREX) United States $0.999B 20.07
Meridian Bioscience (VIVO) United States $0.823B 26.23
Surmodics (SRDX) United States $0.794B 121.41
OraSure Technologies (OSUR) United States $0.772B 43.48
Eagle Pharmaceuticals (EGRX) United States $0.756B 24.24
MacroGenics (MGNX) United States $0.740B 0.00
Cerus (CERS) United States $0.716B 0.00
PetIQ (PETQ) United States $0.705B 20.03
Lantheus Holdings (LNTH) United States $0.625B 19.34
Omeros (OMER) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.540B 26.52
Owens & Minor (OMI) United States $0.535B 6.05
Insys Therapeutics (INSY) United States $0.527B 0.00
NanoString Technologies (NSTG) United States $0.521B 0.00
TG Therapeutics (TGTX) United States $0.444B 0.00
Evolus (EOLS) United States $0.403B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.332B 21.45
Cytosorbents (CTSO) United States $0.313B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.264B 0.00
Surface Oncology (SURF) United States $0.225B 0.00
Rockwell Medical (RMTI) United States $0.214B 0.00
BioLife Solutions (BLFS) United States $0.204B 275.00
Chimerix (CMRX) United States $0.172B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.146B 0.00
Fonar (FONR) United States $0.141B 7.06
Imprimis Pharmaceuticals (IMMY) United States $0.123B 0.00
Chembio Diagnostics (CEMI) United States $0.106B 0.00
United-Guardian (UG) United States $0.080B 16.85
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.066B 21.07
CAS Medical Systems (CASM) United States $0.053B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Capricor Therapeutics (CAPR) United States $0.029B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.018B 0.00
Senestech (SNES) United States $0.017B 0.00
Akers Biosciences Inc (AKER) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00